About the role
Job Title: Senior Manager, IT Infrastructure, Systems & Operations
Location: Princeton, NJ (Hybrid Flexibility)
Reports To: Senior Director, Global Head of Information Technology
About F2G
F2G is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies to treat life-threatening invasive fungal infections. F2G has discovered and developed a completely new class of antifungal agents called the orotomides. The orotomides have a distinct mechanism of action, selectively targeting fungal dihydroorotate dehydrogenase (DHODH), a key enzyme in the de novo pyrimidine biosynthesis pathway. This differentiates the orotomides from the currently marketed antifungal agents. Olorofim (formerly F901318) is F2G’s leading candidate from this class and has fungicidal activity against a broad range of mold infections, including a variety of rare and resistant molds that cause life-threatening infections for which current therapies have limitations or are ineffective.
F2G has completed a Phase 3 randomized clinical study to compare treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with Invasive Fungal Disease Caused by Aspergillus Species and received positive topline data in June 2026. A previous Phase 2b open-label study of olorofim focused on rare and resistant invasive fungal infections including invasive aspergillosis (including azole-resistant strains), coccidioidomycosis and scedosporiosis (including lomentosporiosis). Olorofim has received orphan drug status from the European Medicines Agency and orphan drug status, Qualified Infectious Disease Product (QIDP) designation, and Breakthrough Therapy designation from FDA.